YETI Holdings, Inc. Announces Reporting Date for Second Quarter Fiscal 2025 Financial Results
AUSTIN, Texas–(BUSINESS WIRE)–YETI Holdings, Inc. (“YETI”) (NYSE: YETI) today announced that it plans to report its second quarter fiscal year 2025... Read more.
ENHERTU® Plus Pertuzumab Granted Breakthrough Therapy Designation in the U.S. as First-Line Therapy for Patients with HER2 Positive Metastatic Breast Cancer
Ninth Breakthrough Therapy Designation for Daiichi Sankyo and AstraZeneca’s ENHERTU with the latest based on DESTINY-Breast09 phase 3 trial results Thirteenth... Read more.
QT Imaging Launches QTviewer 2.8 to Enhance Clinical Efficiency and Diagnostic Accuracy
NOVATO, Calif.–(BUSINESS WIRE)–QT Imaging Holdings, Inc. (OTCQB: QTIH), a medical device company engaged in research, development, and commercialization... Read more.
OFG Bancorp Reports 2Q25 Results
SAN JUAN, Puerto Rico–(BUSINESS WIRE)–OFG Bancorp (NYSE: OFG), the financial holding company for Oriental Bank, today reported results for the second... Read more.
Top-Ranked Coastline Real Estate Group Joins Real
Real surpasses 28,000 agents across the U.S. and Canada MIAMI–(BUSINESS WIRE)–$REAX #therealbrokerage–The Real Brokerage Inc. (NASDAQ: REAX), a... Read more.
APi Group Confirms Date of Second Quarter 2025 Earnings Release
NEW BRIGHTON, Minn.–(BUSINESS WIRE)–APi Group Corporation (NYSE: APG) (“APi” or the “Company”) announced today that it intends to release its... Read more.
Webster Reports Second Quarter 2025 EPS of $1.52
STAMFORD, Conn.–(BUSINESS WIRE)–Webster Financial Corporation (“Webster”) (NYSE: WBS), the holding company for Webster Bank, N.A., today announced... Read more.
Cybin Receives UK MHRA Approval to Commence EMBRACE, A Multinational Pivotal Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder
– EMBRACE, the second Phase 3 study within the PARADIGM program, expects to enroll 330 participants at approximately 60 clinical sites across the United States,... Read more.
Elucid Names Richard E. Kuntz, MD, MSc and Shamiram Feinglass, MD, MPH Board Directors
Leaders in clinical, product innovation, and market access will provide guidance for PlaqueIQTM strategy BOSTON & SCCT ANNUAL MEETING, MONTREAL–(BUSINESS... Read more.
PureTech Founded Entity Seaport Therapeutics Announces First Patient Dosed in Phase 2b BUOY-1 Study of GlyphAllo™ (SPT-300) in Major Depressive Disorder (MDD), With or Without Anxious Distress
BUOY-1 builds on successful Phase 1 and Phase 2a data with GlyphAllo – a novel oral prodrug of allopregnanolone and a potential first-in-class treatment for MDD... Read more.